Contents
pdf Download PDF
pdf Download XML
90 Views
17 Downloads
Share this article
Research Article | Volume 18 Issue 11 (November, 2026) | Pages 417 - 423
Histopathological and Biomarker-Based Assessment of Oral Potentially Malignant Disorders: Correlation with Dysplastic Changes and Disease Progression
 ,
 ,
 ,
 ,
 ,
1
Assistant Professor Oral pathology Bacha Khan Dental College Mardan
2
Vice Principal Assistant Professor Oral Biology IIDC Riphah International University Islamabad
3
BDS, MSc OMFS, FCPS OMFS Senior Registrar in Oral Medicine in Fatima Jinnah Dental College & Hospital
4
Assistant Professor Oral and Maxillofacial Surgery . Altamash Institute of Dental Madicine Karachi.
5
FCPS Oral and Maxillofacial Surgery Assistant Professor and Head of Oral medicine and Diagnosis Department Fatima Jinnah Dental College Hospital, Karachi
6
ORAL PATHOLOGY RIPHAH INTERNATIONAL UNIVERSITY
Under a Creative Commons license
Open Access
Received
Oct. 8, 2026
Revised
Oct. 21, 2026
Accepted
Nov. 4, 2026
Published
Nov. 20, 2026
Abstract

Oral potentially malignant disorders (OPMDs) are a risk factor for oral cancer. Histopathological grading is used to detect epithelial dysplasia, and biomarkers can help give more information about abnormalities and disease progression. The expression of Ki-67 and p53 in OPMDs were assessed in the present study and related to histopathological dysplasia. Methodology: A cross sectional analytical study was done in the hospital setting with 100 patients presenting with OPMDs. The epithelial dysplasia was graded as absent, mild, moderate or severe by histopathological examination. Ki-67 and p53 expression was evaluated by immunohistochemistry. The statistical analysis done was chi-square test, ANOVA, Spearman correlation and ordinal logistic regression. Results with a p value of < 0.05 were considered significant. Results: Female was the most common gender, with leukoplakia as the most common type (48%), and 64% of the patients were male. Mild Observed in 10% of cases each, severe dysplasia was observed in 10% of cases each identified in 20%. The level of mean Ki-67 and p53 expression gradually rose with increasing severity of dysplasia (p<0.001). There was a strong positive correlation for dysplasia grade with Ki-67 (r=0.72) and p53 (r=0.68), respectively, (p<0.001). There were significant relationships between both of the biomarkers and the severity of the dysplasia. Conclusion: There were significant associations between increased epithelial dysplasia and Ki-67 and p53 expression. Their combined assessment with conventional histopathology may improve the evaluation of OPMDs and identification of potentially high-risk lesions.

Keywords
INTRODUCTION

Oral potentially malignant disorders (OPMDs) are a collection of oral mucous disorders that are linked to an increased risk of oral cancer. Higher risk of the development of oral squamous cell carcinoma (OSCC) [1].

 

It may be in the oral cavity, as in the case of a toothache. The conditions include leukoplakia, erythroplakia, oral submucous fibrosis and oral lichen planus [2]. Though these lesions do not give rise to raised solid forms of the disease. Need not progress to malignancy, but can show cell and structural changes that make a statement about the risk of cancer [3]. Every child, regardless of their condition, should be identified and assessed as early as possible with the utmost accuracy. Thus OPMDs are a crucial component in the diagnosis, management and prevention of malignant transformation [4].

 

However, there are several potential risk factors for developing OPMDs, including tobacco use, use of betel quid, and certain dietary factors. These are the factors associated with areca nut, gutka, naswar and alcohol consumption [5]. These can lead to chronic epithelial inflammation, oxidative stress, and irritation cause abnormal changes in the cells, which eventually causes genetic changes [6]. Smokeless tobacco use, along with the use of tobacco in general, is prevalent in the South Asian countries including Pakistan and has impacted millions of people in these regions. Oral PML play a major role in the burden of related products [6].

 

The most common technique for diagnosis and evaluation of the severity of OPMDs is by histopathological examination. Of oral epithelial dysplasia [8]. Typically, dysplasia is considered mild, moderate, or severe according to abnormalities of the cells and/or the architecture. Loss of normal epithelial is an important microscopic feature. The hallmark features of this type of cancer include organization, pleomorphism, nuclear hyperchromatism and elevated nuclear-to-cytoplasm ratio.

 

These include abnormal mitotic activity [9]. The severity of dysplasia will give a good indication of malignant transformation risk. Yet, grading on a histopathological basis may be subjective and does not reflect the degree of aggressiveness of the tumor. It can always correctly estimate the biological reaction of a single lesion [10].

 

The importance of biomarkers as complementary tools to assess cellular abnormalities has grown malignant transformation potential. Ki-67 is a cellular proliferation marker which suggests higher cell proliferation. The encoded protein plays a role in division, whereas p53 is a tumour suppressor protein that functions in DNA repair, cell-cycle regulation and. apoptosis [11]. Disruption of these markers' expression can suggest that there is abnormal proliferation of the epithelium. It disrupts normal cell regulation [12]. Other biomarkers, such as p16, cyclin D1 and Bcl-2 have also been studied for their role in the detection of molecular alterations related to oral carcinogenesis [13].

 

Histopathological analysis along with biomarker evaluation could offer a more A comprehensive understanding of OPMDs is provided. histochemistry detects biochemical alterations. Morphological changes are detected by histopathology and biochemical changes by histochemistry. The severity of dysplasia is determined by the type of cell, while biomarkers provide more information about the severity of dysplasia. Proliferation and abnormalities at the molecular level. Their joint evaluation can enhance the identification of lesions that have characteristics linked to a higher probability of malignant transformation [14].

 

Research Gap

Although there have been progress in histopathological and molecular evaluation, the prediction of the malignant transformation of OPMDs is still difficult. Histopathological grading may not fully reflect the biological behaviour of lesions and the association of the expression of the biomarkers with the stage of dysplasia is yet to be investigated. There was low incorporation of histopathological results and biomarker expression, especially in high-exposure oral cancers patient population, indicating the need for future studies.

 

Objective

The aim of this study is to assess the histopathological features and the expression of biomarkers in OPMDs and its relation with the presence and grade of EPMD. It also seeks to evaluate the potential of biomarker assessment as a complementary tool to the traditional histopathological assessment to detect lesions that are at higher risk of malignant transformation.

MATERIALS AND METHODS

Study Design, Setting, and Duration

The present study, a cross sectional analytical study was carried out in the department of Oral Pathology and Histopathology for a period of 12 months. This study assessed the association between the grade of oral epithelial dysplasia and Ki-67 and p53 immunohistochemical expression in patients with oral potentially malignant disorders (OPMDs).

 

Sample Size and Sampling Technique

There were 100 patients who were included using non-probability consecutive sampling. The sample size was determined by the correlation based formula, using an expected correlation coefficient of 0.30, 95% confidence level and 80% statistical power. The calculated minimum sample size was 85, which was raised to 98 by adding 15% due to insufficient specimens and staining. The last sample consisted of 100 patients.

 

Eligibility Criteria

All patients were included who had clinically suspected, histopathologically confirmed OPMDs and sufficient formalin fixed, paraffin embedded tissue samples. Patients with prior diagnosis of oral squamous cell carcinoma, history of chemotherapy or radiotherapy for oral malignancy, inadequate tissue specimens, extensive necrosis, and inadequate epithelium were excluded and failed immunohistochemical staining.

 

Clinical Assessment and Histopathological Examination

The demographic and clinical data (age, gender, tobacco use, betel quid or areca nut consumption, alcohol use, lesion site, and clinical appearance) were recorded on a structured proforma. A sample of incisional or excisional biopsies were taken and fixed in 10% neutral buffered formalin. Specimens were routinely processed and embedded in paraffin wax for cutting into 3-5 µm sections. Histological sections were stained with hematoxylin and eosin (H&E) and analysed with the light microscope.

The architectural and cytological changes such as irregular stratification, loss of basal cell polarity, nuclear hyperchromatism, cellular pleomorphism, increased nuclear-to-cytoplasmic ratio, abnormal mitotic figures, premature keratinization, and abnormal rete ridge formation were evaluated for diagnosis of oral epithelial dysplasia. Lesions were graded as non-dysplastic, mild, moderate, and severe dysplasia.

 

Immunohistochemical Analysis

Paraffin embedded tissue sections were stained with immunohistochemistry for evaluation of the expression of Ki-67 and p53. Sections were deparaffinized, rehydrated and then underwent antigen retrieval. Hydrogen peroxide was used to block endogenous peroxidase, and primary antibodies against Ki-67 and p53 were then used. A proper secondary antibody detection system was used and immunoreactivity was detected with 3,3′-diaminobenzidine (DAB) and then counterstained with hematoxylin. The proper positive and negative controls were employed.

 

The Ki-67 expression was calculated by counting the percentage of Ki-67-positive epithelial cell nuclei to the total number of epithelial cells in representative fields of view. In the case of p53, the percentage of epithelial cells with nuclear immunoreactivity was documented, as well as the intensity and distribution of immunoreactivity. Comparisons of both biomarkers were made between the grades of epithelial dysplasia.

Quality Control

The slides with the histopathological and immunohistochemical staining were examined independently by two qualified pathologists who were not aware of the other pathologist's interpretations. Consensus review was used to settle any disputes. Suitable staining controls and standardised procedures were employed to provide satisfactory evaluation.

 

Statistical Analysis

IBM SPSS version 27.0 was used to analyze the data. Categorical data is presented in frequencies and percentages and continuous data is presented as mean ± standard deviation or as median (interquartile range) according to the type of data. The Shapiro–Wilk test was used to determine normality. Chi-square test or Fisher's exact test was used for categorical variables to assess the association. The differences in the expression of Ki-67 and p53 between the dysplasia grades were compared using One-way ANOVA or Kruskal–Wallis test, as appropriate, and appropriate post hoc comparisons were provided.

 

Spearman's rank correlation methods were used to analyse the relationship between the severity of dysplasia and the levels of expression of the markers. Where appropriate, to determine independent associations after adjustment for clinical and demographic factors, ordinal logistic regression was used. The p value was considered statistically significant if it was < 0.05 on both sides.

RESULTS

There were 100 patients with oral potentially malignant disorders (OPMDs) included in the study. The study population comprised relatively young-to-middle aged with a predominant male population. The exposures most commonly reported were smokeless tobacco; betel quid/areca nut use; and cigarette smoking. The most common clinical pattern was leukoplakia, however other potentially malignant oral lesions were also noted such as oral submucous fibrosis, erythroplakia and oral lichen planus. Demographic and clinical characteristics of the study population are shown in Table 1.

 

Table 1. Demographic and Clinical Characteristics of the Study Population (n=100)

Variables

Frequency (n)

Percentage (%)

Age groups (years)

 

 

18–40

32

32.0

41–60

48

48.0

Above 60

20

20.0

Gender

 

 

Male

64

64.0

Female

36

36.0

Risk factors

 

 

Smokeless tobacco use

57

57.0

Betel quid/areca nut use

31

31.0

Smoking

22

22.0

Alcohol consumption

15

15.0

Clinical lesion type

 

 

Leukoplakia

48

48.0

Oral submucous fibrosis

25

25.0

Erythroplakia

12

12.0

Oral lichen planus

15

15.0

Histopathological evaluation showed that there was heavy epithelial dysplasia among which moderate and mild dysplasia were the most common grade. Other abnormalities such as architectural and cytological ones were also often present. The architectural alterations that were most prominent were irregular stratification of the epithelium while the most frequently observed cytological abnormality was nuclear hyperchromatism, with cellular pleomorphism next. These results suggest significant morphological changes among the analyzed specimens of OPMD. Table 2 shows a summary of the distribution of dysplasia grades and individual microscopic abnormalities.

 

Table 2. Histopathological Distribution and Microscopic Features (n=100)

Histopathological findings

Frequency (n)

Percentage (%)

Dysplasia grade

 

 

Non-dysplastic

20

20.0

Mild

30

30.0

Moderate

30

30.0

Severe

20

20.0

Architectural abnormalities

 

 

Irregular epithelial stratification

58

58.0

Loss of basal cell polarity

43

43.0

Abnormal rete ridge formation

39

39.0

Premature keratinization

34

34.0

Cytological abnormalities

 

 

Nuclear hyperchromatism

62

62.0

Cellular pleomorphism

54

54.0

Increased nuclear-to-cytoplasmic ratio

49

49.0

Abnormal mitotic figures

28

28.0

Immunohistochemical analysis showed varying expression in the study population of Ki-67 and p53. Ki-67 compared to p53 had a relatively higher mean labeling index and wide range of expression. The observed differences in both markers indicate that cellular proliferative activity and immunoreactivity of p53 varies between different OPMD lesions. The overall expression characteristics of their immunohistochemistry are shown in Table 3.

 

Table 3. Overall Immunohistochemical Expression of Ki-67 and p53 (n=100)

Biomarker

Mean (%)

SD

Minimum–Maximum

Ki-67 labeling index

19.6

13.2

1–55

p53-positive cells

15.3

11.5

0–48

There was a progressive rise in expression of both Ki-67 and p53 with increasing histopathological severity. Both biomarkers showed the lowest expression in non-dysplastic lesions, and showed increasing expression in mild, moderate and severe dysplasia. This gradient was more pronounced for Ki-67, but was also observed for p53. The mean expression of both biomarkers were demonstrated to be statistically significant different in both across the four histopathological categories (Table 4).

Table 4. Comparison of Ki-67 and p53 Expression According to Dysplasia Grade

Dysplasia grade

n

Ki-67 mean ± SD (%)

p53 mean ± SD (%)

Non-dysplastic

20

4.8 ± 2.5

3.9 ± 2.1

Mild

30

11.5 ± 4.2

9.2 ± 3.8

Moderate

30

23.1 ± 6.8

18.4 ± 6.1

Severe

20

37.2 ± 8.5

29.7 ± 8.0

Overall

100

19.6 ± 13.2

15.3 ± 11.5

ANOVA p-value

 

<0.001

<0.001

The percentage of lesions with high levels of expression of both Ki-67 and p53 was also correlated with increasing histopathological severity. All cases of severe dysplasia showed high levels of Ki-67, whereas moderate dysplasia cases had 93.3% and mild dysplasia cases had 50% of their specimens expressing high levels of Ki-67. Likewise, 95.0% of severe dysplasia grade, 83.3% of moderate dysplasia grade, and 43.3% of mild dysplasia grade had high level of p53 expression. Grade of dysplasia was significantly associated with both biomarkers (Table 5).

 

Table 5. Association Between Categorical Biomarker Expression and Dysplasia Grade

Dysplasia grade

Ki-67 low n (%)

Ki-67 high n (%)

p53 low n (%)

p53 high n (%)

Non-dysplastic

18 (90.0)

2 (10.0)

19 (95.0)

1 (5.0)

Mild

15 (50.0)

15 (50.0)

17 (56.7)

13 (43.3)

Moderate

2 (6.7)

28 (93.3)

5 (16.7)

25 (83.3)

Severe

0 (0.0)

20 (100.0)

1 (5.0)

19 (95.0)

Total

35 (35.0)

65 (65.0)

42 (42.0)

58 (58.0)

Chi-square p-value

 

<0.001

 

<0.001

Strong positive correlation was found between dysplasia severity and Ki-67 and p53 expression with slightly better correlation with Ki-67 (Spearman correlation analysis). Both biomarkers were also significantly correlated with each other. In adjusted ordinal logistic regression, Ki-67 and p53 expression remained significantly correlated with the severity of dysplasia; for every 1% increase in expression, there was a 12% and 7% increase in odds of increasing dysplasia severity, respectively. Age and gender were statistically not associated with dysplasia severity though smokeless tobacco exposure was. The results of these analyses indicate that the expression of each of these immunohistochemical markers is independently associated with histopathological severity; these associations are shown in Table 6.

Table 6. Correlation and Multivariable Analysis of Biomarkers and Dysplasia Severity

Variables

Statistical measure

Estimate

95% CI

p-value

Ki-67 vs. dysplasia grade

Spearman's rho

0.72

—

<0.001

p53 vs. dysplasia grade

Spearman's rho

0.68

—

<0.001

Ki-67 vs. p53

Spearman's rho

0.64

—

<0.001

Ki-67 expression

Adjusted OR

1.12

1.07–1.17

<0.001

p53 expression

Adjusted OR

1.07

1.02–1.12

0.004

Age

Adjusted OR

1.02

0.99–1.05

0.180

Male gender

Adjusted OR

1.31

0.61–2.82

0.487

Smokeless tobacco exposure

Adjusted OR

2.48

1.10–5.59

0.028

OR = odds ratio; CI = confidence interval. Regression odds ratios for Ki-67 and p53 represent each 1% increase in biomarker expression.

 

DISCUSSION

In the present study, the relationship between the histopathological findings of dysplasia and the expression of Ki-67 and p53 has been evaluated in 100 patients diagnosed with OPMD. The findings showed a progressive increase in the severity of the biomarkers with increasing severity of epithelial dysplasia. They found that the level of expression of Ki-67 was positively associated with that of p53 and dysplasia grade, indicating their potential as additional markers of abnormal changes in the epithelium [15].

 

High prevalence of use of smokeless tobacco and preponderance of male patients was consistent with above what has been found in other South Asian populations [16]. The most prevalent condition was leukoplakia, accounting for 24.4% of all the cases. In the present study, along with earlier study it was observed to be one of the most observed OPMDs [17]. Past studies have shown that malignant tumors of the thyroid gland are treatable. The chances of transformation are dependent on the type of lesion, clinical features and histopathological severity [18].

 

The progressive increase in Ki-67 expression from non-dysplastic lesions to severe dysplasia was consistent with previous immunohistochemical investigations demonstrating increased epithelial proliferative activity in higher grades of oral epithelial dysplasia [19]. Recent systematic review evidence has also supported the usefulness of Ki-67 in evaluating and grading oral potentially malignant disorders.

 

Similarly, the increased p53 expression observed with increasing dysplasia severity was supported by previous studies investigating tumor suppressor abnormalities in OPMDs. A systematic review and meta-analysis reported that p53 overexpression was associated with an increased risk of malignant transformation, supporting its potential role in oral cancer risk assessment [20].

 

.The important correlations and multivariable analysis results confirmed The value of using a combination of biomarker analysis and conventional histopathological analysis. It is noted, however, that literature citations to date have focused on the fact that none of the current biomarkers are able to accurately predict malignant. Transformation in all patients. An integrated approach, combining histopathological results, molecular, and imaging data will be used. A more complete assessment of risk can be undertaken using markers and clinical risk factors [21].

 

Limitations

There were a few drawbacks to the study. It was not possible to directly assess long-term effects from its cross-sectional design. The single centre and relatively small sample size may have restricted the the applicability of the results. Moreover, only two biomarkers were tested, Ki-67 and p53. There may have been interobserver differences in the staining and interpretation of the immunohistochemical markers.

 

Future Recommendations

Future multicenter studies with larger sample sizes and longitudinal follow-up are recommended to determine the actual malignant transformation risk of OPMDs. Additional biomarkers, including p16, cyclin D1, and Bcl-2, could also be investigated. Standardized immunohistochemical scoring and combined clinical, histopathological, and molecular assessment may improve risk stratification and support early identification of high-risk lesions.

CONCLUSION

Repeat multicenter studies with larger numbers of participants and longer follow-up are recommended determine the actual malignant transformation risk of OPMDs. A number of other markers, such as p16, and other proteins such as cyclin D1, and Bcl-2, may be studied. The use of a standardized immunohistochemical score and a clinical, histopathological and molecular evaluation combined may aid in risk stratification facilitate early detection of high risk lesions.

REFERENCES
  1. Sunny SP, DR R, Hariharan A, Mukhia N, Gurudath S, G K, Raghavan S, Kolur T, Shetty V, R VB, Surolia A. CD44-SNA1 integrated cytopathology for delineation of high grade dysplastic and neoplastic oral lesions. PLoS One. 2023 Sep 25;18(9):e0291972.https://doi.org/10.1371/journal.pone.0291972
  2. Uzun H, Bozarslan G, Dumur S, Misirlioglu NF, Elgormus MN, Duvarcı C, Gelisgen R, Karaaltin AB, Yilmaz YZ. Diagnostic Value of Serum and Salivary Podoplanin as Clinical Biomarkers for Distinguishing Oral Cancer from Oral Leukoplakia. Diagnostics. 2026 Jan 9;16(2):206.https://doi.org/10.3390/diagnostics16020206
  3. Rivera C, Gallegos R, Figueroa C. Biomarkers of progression to oral cancer in patients with dysplasia: A systematic review. Molecular and clinical oncology. 2020 Nov;13(5):42. https://doi.org/10.3892/mco.2020.2112
  4. Vitorino R. Translational mapping of mechanistic and biomarker‐driven clinical trials in oral squamous cell carcinoma and oral potentially malignant disorders. Annals of the New York Academy of Sciences. 2025 Aug;1550(1):349-66.https://doi.org/10.1111/nyas.15405
  5. Fatih MT, Mahmood MK, Garib BT, Amin YM, Talabani RM, Rasheed TA, Kurda HA, Qadir BH, Noori ZF, Abdulghafor MA, Saeed AO. Malignant transformation of oral leukoplakia and proliferative verrucous leukoplakia and its biomarker predictors: a systematic umbrella review. Head & neck. 2026 Jan;48(1):246-60.https://doi.org/10.1016/j.joms.2026.02.007
  6. Sundaresan S. Molecular and microenvironmental drivers of malignant transformation from oral potentially malignant disorders to oral squamous cell carcinoma. Frontiers in Oncology. 2026 Jun 3;16:1856931.https://doi.org/10.3389/fonc.2026.1856931
  7. Habibi-Tanha, K., Ménès, J., Gigliotti, J. et al. Biomarker-based machine learning for malignant transformation in oral potentially malignant disorders: a scoping review. BMC Oral Health 26, 1381 (2026). https://doi.org/10.1186/s12903-026-08943-x
  8. Dimitropoulou P, Fytros F, Charisi C, Syrioti A, Spantidakis N, Poulopoulos K, Fasoula M, Karagiannidis E, Poulopoulos A, Zisis V. Podoplanin and Selected Cancer Stem Cell or Stemness-Associated Markers in Oral Epithelial Dysplasia: A Structured Narrative Review of Their Role in Malignant Transformation and Risk Stratification. Reports. 2026 Sep 20;9(3):316.https://doi.org/10.3390/reports9030316
  9. Troka ME, Gates JC. Predicting Oral Cancer From Precursor Lesions: Assessing Current Methods and Future Directions. JCO Precision Oncology. 2026 Sep;10(9):e2600107.https://doi.org/10.1200/PO-26-00107
  10. Rosa AC. Salivary Biomarkers in the Diagnosis and Prognosis of Oral Disease. InSalivary Analysis-Biomarkers, Clinical Applications, and Emerging Technologies 2025 Apr 17. IntechOpen. DOI: 10.5772/intechopen.1010199
  11. Bhagwath S. Histopathological and Molecular Characterization of Potentially Malignant Oral Disorders for Early Diagnosis and Prognostic Assessment. Journal of Intelligent Decision Making and Information Science. 2026 Aug 8;3(6s):1473-82.https://doi.org/10.59543/jidmis.v3.1513
  12. Varela E. Artificial Intelligence and Biomarker Integration in Oral Pathology: Transforming Early Detection and Risk Prediction of Oral Potentially Malignant Disorders. J Dental Health Oral Res. 2026; 7 (2): 1-11.https://doi.org/10.46889/JDHOR.2026.7222
  13. Manikandhan R, Arya S, Khanna V. PROGNOSTIC ROLE OF ΓH2AX AND OTHER BIOMARKERS IN MALIGNANT TRANSFORMATION OF ORAL POTENTIALLY MALIGNANT DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Genetics and Molecular Research. 2026 Jun 2. https://doi.org/10.4238/sqk4kb04
  14. Groenevelt, M.C.C., Meulenbroeks, L., Brakenhoff, R.H. et al. Non-invasive detection and monitoring of oral squamous cell carcinoma and oral potentially malignant disorders: an umbrella review on diagnostic accuracy. Clin Oral Invest 30, 421 (2026). https://doi.org/10.1007/s00784-026-07109-x
  15. Mohsen M, Pergolini D, Purrazzella A, Pierini E, Pranno N, Romeo U, Polimeni A, Palaia G. Diagnostic Performance of a Point-of-Care Salivary Biomarker-Based Test for Oral Potentially Malignant Disorders: A Case–Control Clinical Study. Applied Sciences. 2026 Sep 21;16(18):9379. https://doi.org/10.3390/app16189379
  16. Brockmeyer P. Prognostic biomarkers in oral squamous cell carcinoma: current evidence and future directions. Frontiers in Oncology. 2025 Dec 5;15:1692294.https://doi.org/10.3389/fonc.2025.1692294
  17. Yilmaz, B., Ozpolat, B. (2026). The Role of Proinflammatory Biomarkers in Oral Cancer Pathophysiology. In: Rezaei, N., Ziaei, H. (eds) Oral Immunology. Advances in Experimental Medicine and Biology, vol 1492. Springer, Cham. https://doi.org/10.1007/978-3-032-03176-1_17
  18. Şengün DN, Faruk Kocamaz Ö, Kitap MC, Soluk Tekkeşin M. Emerging Diagnostic Strategies for Oral Cancer and Oral Potentially Malignant Disorders: A PRISMA-Guided Scoping Review. Diagnostics. 2026 Apr 30;16(9):1364.10.3390/diagnostics16091364
  19. Marmo GM, Munzone M, Polizzi A, Campagna R, Mascitti M, Isola G. Genetic and epigenetic biomarkers for the early oral cancerization risk in periodontitis patients. Current Issues in Molecular Biology. 2025 Nov 9;47(11):933.https://www.mdpi.com/1467-3045/47/11/933
  20. Hwang, J.T.K., Dammling, C., McCord, C. et al. External Validation of Straticyte™, a Quantitative Biomarker-Based Risk Assay in Predicting Oral Cancer. J. Maxillofac. Oral Surg. 24, 1351–1357 (2025). https://doi.org/10.1007/s12663-024-02362-7
  21. de Vicente JC, Donate-Pérez del Molino P, Rodrigo JP, Allonca E, Hermida-Prado F, Granda-Díaz R, Rodríguez Santamarta T, García-Pedrero JM. SOX2 expression is an independent predictor of oral cancer progression. Journal of clinical medicine. 2019 Oct 21;8(10):1744.https://www.mdpi.com/2077-0383/8/10/1744.

 

Recommended Articles
Research Article
Anatomy of the Danger Zones: Relationship Between Nerve-Sparing Surgical Techniques and Chronic Postoperative Pain Following Laparoscopic Inguinal Hernia Repair.
...
Published: 21/11/2026
Research Article
Prenatal and Postnatal Risk Factors for Retinopathy of Prematurity: A Prospective Analysis of 250 Preterm Neonates
...
Published: 21/11/2026
Research Article
Anatomical Variations of the inferior Epigastric Vessels and their Association with Port site Complications Following Laparoscopic Abdominal Surgery: A Comparative Cross-Sectional Study
...
Published: 20/11/2026
Research Article
Undernutrition, incomplete immunization and prior respiratory morbidity as determinants of severe pneumonia in children aged 2–59 months: a hospital-based case-control study from North Maharashtra, India
...
Published: 30/01/2026
Chat on WhatsApp
© Copyright CME Journal Geriatric Medicine